Enterprise Value

2.644B

Cash

103.7M

Avg Qtr Burn

-10.47M

Short % of Float

0.42%

Insider Ownership

0.01%

Institutional Own.

2.43%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Update

Phase 2/3

Data readout

Eftilagimod Alpha Details
Cancer, Soft tissue sarcoma

Phase 2

Data readout

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) + Keytruda Details
Cancer, Head and neck cancer, Head and neck squamous cell carcinoma

Phase 2

Update

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Initiation

Failed

Discontinued